Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.76), $0.07 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $85 million versus the consensus estimate of $65.8 million.

GUIDANCE:

Novavax sees FY2024 revenue of $650-700 million, versus the consensus of $761.5 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.